Multiplication of defective Ebola virus in a complementary permissive cell line

Xian-Kun Tong,Heng Li,Li Yang,Shi-Zhe Xie,Sha Xie,Ying Gong,Cheng Peng,Xiao-Xiao Gao,Zheng-Li Shi,Xing-Lou Yang,Jian-Ping Zuo
DOI: https://doi.org/10.1016/j.antiviral.2022.105491
IF: 7.6
2022-12-14
Antiviral Research
Abstract:In an effort to develop safe and innovative in vitro models for Ebola virus (EBOV) research, we generated a recombinant Ebola virus where the glycoprotein (GP) gene was substituted with the Cre recombinase (Cre) gene by reverse genetics. This defective virus could multiply itself in a complementary permissive cell line, which could express GP and reporter protein upon exogenous Cre existence. The main features of this novel model for Ebola virus are intact viral life cycle, robust virus multiplication and normal virions morphology. The design of this model ensures its safety, excellent stability and maneuverability as a tool for virology research as well as for antiviral agent screening and drug discovery, and such a design could be further adapted to other viruses.
pharmacology & pharmacy,virology
What problem does this paper attempt to address?